Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against ARS Pharmaceuticals Inc. ("ARS" or the "Company") (NASDAQ: SPRY) on behalf of investors that purchased or otherwise acquired ARS securities between March 9, 2026 and June 24, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in ARS and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox...
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot UlcersLakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class,...
- XORTX Therapeutics Inc.XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market OpportunityInvestigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026
- Corcept Therapeutics IncorporatedCorcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)REDWOOD CITY, Calif., September 18, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined w
- Theralase Technologies Inc.Correcting and Replacing: Theralase(R) Releases Q2 2026 Financial StatementsTheralase® Provides Updates on its Phase II Bladder Cancer Clinical Study and Oncology PipelineThis Press Release adds omitted safety and prescribing information about Adstiladrin® (nadofaragene firadenovec-vncg)Toronto, Ontario--(September 18, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical-stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and...
- ACROBiosystems deepens its France presence with a dedicated hub at The HIVE Innovation Center, embedding into the Campus Grand Parc ecosystemKadans Science Partner is pleased to welcome ACROBiosystems to The HIVE Innovation Center, its laboratory and office building dedicated to the life sciences, situated on the Campus Grand Parc in Villejuif. A global biotechnology company dedicated to...
- Japan Digital Therapeutics Market Set for Strong Growth Through 2035, Driven by Innovative Solutions, Evolving Therapy Models and Expanding Opportunities Across Key Therapeutic AreasJapan’s digital therapeutics market is gaining momentum as aging, chronic disease demand, regulatory support, insurance coverage, AI and B2B partnerships accelerate adoption.
- AI in Precision Medicine Market Poised for Strong Growth Through 2040, Driven by Technology Innovation, Expanding Therapeutic Applications and Global Adoption OpportunitiesAI-driven genomics, predictive diagnostics, digital pathology and drug discovery are expanding personalized care, creating opportunities in partnerships, secure data platforms and localized infrastructure.
- AI in Genomics Market Set for Transformative Growth Through 2040, Driven by Advanced Technologies, Expanding Applications and Rising Global AdoptionAI is accelerating genomic analysis, drug discovery, precision medicine and CRISPR, creating opportunities in multi-omics, generative AI, diagnostics and industry partnerships.
- Investeringsforeningen IA Invest – Udskydelse af overflytning af tre afdelingerI forlængelse af foreningens meddelelse af 23. juni 2026 om generalforsamlingens vedtagelse af overflytning af afdelingerne Strategic Danske Aktier, Advice Capital Global og Advice Capital Breakthrough Biotech til Investeringsforeningen PortfolioManager, skal det hermed oplyses, at overflytningen af de tre afdelinger er blevet udskudt, da Finanstilsynet endnu ikke har godkendt overflytningen.
- Halozyme Therapeutics, Inc.Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company"), today announced the pricing of $1.3 billion aggregate principal amount of 1.50% convertible senior notes due 2033 (the "Convertible Notes"). The offering size was increased...
- Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public OfferingElectra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines for the treatment of immune-mediated diseases and cancer, today announced the pricing of its upsized initial public offering of 23,333,334 shares of common stock at a price to the public of $15.00 per share. The gross proceeds to Electra from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Electra, are expected to be approximately $350.0 million. In addition, Electra has granted the underwriters a 30-day option to purchase up to an additional 3,500,000 shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Electra.